News
Hardman & Co Research: City of London Investment Group (CLIG) - Performance pays dividends
Hardman & Co Research: City of London Investment Group (CLIG) - Performance pays dividends
Interim Results for the Six Months Ended 30 June 2023
Interim Results for the Six Months Ended 30 June 2023
Hardman & Co Research on City of London Investment Group (CLIG): Positive markets offset by revenue margins
Hardman & Co Research on City of London Investment Group (CLIG): Positive markets offset by revenue margins
Portfolio company Disc Medicine raises $157.8 million in public offering
Portfolio company Disc Medicine raises $157.8 million in public offering
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
Portfolio company Ensoma announces closing of Series B Extension
Portfolio company Ensoma announces closing of Series B Extension
Hardman & Co Research | City of London Investment Group (CLIG): Positive markets offset by revenue margins
Hardman & Co Research | City of London Investment Group (CLIG): Positive markets offset by revenue margins
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Full Year results now to be released on 25 April 2023
Full Year results now to be released on 25 April 2023
Hardman & Co Q&A on City of London Investment Group (CLIG): Continuing its good performance
Hardman & Co Q&A on City of London Investment Group (CLIG): Continuing its good performance